China's AnchorDx completes $40m Series C
AnchorDx, a China-based medical technology developer focused on DNA sequencing and diagnostics, has raised a $40 million Series C round led by OrbiMed and WuXi Huiying Investment.
The company describes itself as the world-leading developer of DNA methylation next-generation sequencing (NGS) products. NGS technology allows for the determination of DNA sequences, which helps researchers...
More on Greater China
Latest News
True North exits India's RDC Concrete after 16-year hold
True North has agreed to sell India-based RDC Concrete, a company it has owned since 2005, to private equity-backed online construction marketplace Infra.market.
India's Freshworks flourishes on NASDAQ debut
Freshworks, one of India's leading software-as-a-service (SaaS) businesses, traded strongly on its NASDAQ debut following a $1 billion IPO.
FountainVest buys New Zealand pet food business
China-focused private equity firm FountainVest Partners has agreed to buy Ziwi, New Zealand’s leading exporter of pet food.